Definitive Contract 75N93023C00012
Award Date
7/1/23
Potential Completion Date
4/15/25
Potential Value
$4.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Pluri Biotech LTD
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Israel
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,499,688.00 cost-plus-fixed-fee definitive contract with Innovation Pathways, LLC to support the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is not a set-aside. The contract was sourced from a Broad Agency Announcement (BAA) seeking proposals...
This is a definitive, cost-no-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cleveland Biolabs, Inc. to develop a therapy for hematopoietic syndrome resulting from acute radiation exposure. The contract, which does not have a set-aside designation, has a ceiling value of $21,956,799.00 and an ultimate completion date of October 15, 2010. As the prime contractor, Cleveland Biolabs, Inc. is responsible for delivering the...
This is a $36,967,744.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Asell, LLC for the advanced development, validation, and FDA clearance of the CellRadX point-of-care biodosimetry system. The contract is not set-aside. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for the advanced...
This is a $100,361,311 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the non-profit research organization MRIGlobal, also known as Midwest Research Institute, for the development of "Biodosimetry High-Throughput Diagnostic Tests." The contract supports the creation of diagnostic tests to evaluate radiation exposure, which is a critical capability for public health emergency preparedness. As a prime contractor,...
This federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID) to Ceramedix Holding, LLC, a small disadvantaged business, is for the development of an anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The $4,723,612.00 cost-plus-fixed-fee contract has a performance period through June 30, 2026. The contract involves two major subcontractors: the Sloan-Kettering Institute for Cancer Research, a non-profit...
This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
<p>This is a cost-plus-fixed-fee contract awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to RxBio, Inc., a for-profit organization, for the IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome. The contract has a potential value of $4,591,511.92 and a completion date of October 31, 2022. The contract was not set aside for any specific business type.</p>
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $5,379,349.00 cost-plus-fixed-fee definitive contract to Chromologic LLC, a minority-owned limited liability company, for the development of MIDOS: A MICRORNA BIODOSIMETER. This contract supports research and development of biodosimetry approaches to assess and medical countermeasures to mitigate or treat acute and/or delayed radiation injuries. The contract aims to develop safe and effective medical countermeasures that...
This is a Firm Fixed Price (FFP) contract awarded by the U.S. Army Medical Command (MEDCOM) to Technology Holding LLC, a small business, for a Small Business Innovation Research (SBIR) Phase II project titled "Novel Biologic Countermeasure for Acute Radiation Syndrome." The contract has a ceiling value of $2,999,993.84 and a period of performance from June 2022 to October 2025. The R&D effort is focused on developing a novel biologic countermeasure to address acute radiation...
This is a $10,299,171.18 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Humanetics Corp, a for-profit biopharmaceutical company. The contract is for an NHP (non-human primate) efficacy study of BIO 300, a therapeutic candidate being developed by Humanetics to mitigate radiation-induced pneumonitis and pulmonary fibrosis. This work builds on Humanetics' prior federal grants from agencies like NIH, DoD, and the Army for research and...